In order to deliver a personalised, responsive service and to improve the site, we remember and store information about how you use it. This is done using simple text files called cookies which sit on your computer. By continuing to use this site and access its features, you are consenting to our use of cookies. To find out more about the way drugeruptiondata.com uses cookies please read our 'Cookie Policy'.
Adverse reactions attributed to entire drug class 'Poly (ADP-ribose) polymerase (PARP) inhibitor'
Please login to view adverse reactions.
Cardiovascular adverse effect (includes major adverse cardiovascular events (MACE))
- (2023): Palazzo A+, ESMO Open Mar, Online ahead of print5% [REVIEW]
Gastrointestinal adverse reaction
- (2020): Hao J+, Crit Rev Oncol Hematol Nov, Online ahead of print [REVIEW]
- (2023): Maiorano BA+, Target Oncol Nov, Online ahead of print [REVIEW] (association)
- (2021): Zeng J+, Zhonghua Fu Chan Ke Za Zhi (Chinese) 56(6), 401-40740%
- (2024): Dai MF+, Expert Rev Anticancer Ther May, Online ahead of print [REVIEW] (pharmacovigilance / pharmacoepidemiology)
- (2021): Liu X+, Front Oncol Oct (e-Collection) [REVIEW]
- (2021): Zhang M+, J Cancer Res Ther 17(7), 1672-1678 [REVIEW]
- (2020): Hao J+, Crit Rev Oncol Hematol Nov, Online ahead of print [REVIEW]
- (2020): Jiang Y+, Front Oncol Jul (e-Collection) [REVIEW]
- (2020): Morice PM+, Lancet Haematol Dec, Online ahead of print [REVIEW]
- (2020): Morice PM+, Lancet Haematol Dec, Online ahead of print [REVIEW]
Neutropenia (neutrophils decreased)
- (2023): Maiorano BA+, Target Oncol Nov, Online ahead of print [REVIEW] (association)
Thrombocytopenia / platelets decreased
- (2023): Maiorano BA+, Target Oncol Nov, Online ahead of print [REVIEW] (association)
Adverse effects / adverse reactions
- (2024): Uekusa R+, Sci Rep Jun, Online ahead of print (181 patients with ovarian cancer who received olaparib or niraparib)
- (2023): Cecere SC+, Expert Opin Drug Saf Sep, Online ahead of print
- (2023): Society Of Obstetrics And Gynecology OZMA+, Zhejiang Da Xue Xue Bao Yi Xue Ban 51(6), 765-774 [REVIEW]
- (2022): Luo J+, Front Oncol Jun (e-Collection) [REVIEW]
- (2022): Yamaoka K+, Life (Basel) 12(9), 1355 [REVIEW]
- (2021): Jesus M+, Expert Opin Drug Saf Oct, Online ahead of print [REVIEW]
- (2020): Shao F+, Biosci Rep Feb, Epub ahead of print55% (grade 3–4 (serious, 26%)) [REVIEW]
- (2020): Xu Y+, Front Oncol Feb (e-Collection) [REVIEW]
- (2020): Yang Y+, World J Surg Oncol 18(1), 151 [REVIEW]
